These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 32691471)
1. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. Shimizu T; Koga T; Furukawa K; Horai Y; Fujikawa K; Okada A; Okamoto M; Endo Y; Tsuji S; Takatani A; Umeda M; Fukui S; Sumiyoshi R; Kawashiri SY; Iwamoto N; Igawa T; Ichinose K; Tamai M; Sakamoto N; Nakamura H; Origuchi T; Mukae H; Kuwana M; Kawakami A J Intern Med; 2021 Feb; 289(2):206-220. PubMed ID: 32691471 [TBL] [Abstract][Full Text] [Related]
2. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease. Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983 [TBL] [Abstract][Full Text] [Related]
3. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922 [TBL] [Abstract][Full Text] [Related]
4. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212 [TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease. Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718 [TBL] [Abstract][Full Text] [Related]
7. Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease. Li L; Wang Q; Wen X; Liu C; Wu C; Yang F; Zeng X; Li Y Oncotarget; 2017 Sep; 8(44):76129-76140. PubMed ID: 29100298 [TBL] [Abstract][Full Text] [Related]
8. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Guo L; Zhang X; Pu W; Zhao J; Wang K; Zhang D; Hong S; Ma Y; Wang X; Ye S; Guo Q; Wang J Rheumatology (Oxford); 2023 Jun; 62(6):2320-2324. PubMed ID: 36637178 [TBL] [Abstract][Full Text] [Related]
9. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595 [TBL] [Abstract][Full Text] [Related]
10. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Hensgens MPM; Delemarre EM; Drylewicz J; Voortman M; Krol RM; Dalm VASH; Miedema JR; Wiertz I; Grutters J; Limper M; Nierkens S; Leavis HL Rheumatology (Oxford); 2022 Oct; 61(10):4087-4096. PubMed ID: 35048953 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718 [TBL] [Abstract][Full Text] [Related]
12. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases. Cheng L; Xu L; Xu Y; Yuan F; Li J; Wu M; Da Z; Wei H; Zhou L; Yin S; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Liu H; Ren T; Zang Y Clin Rheumatol; 2024 Jan; 43(1):339-347. PubMed ID: 37985533 [TBL] [Abstract][Full Text] [Related]
13. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis. Li C; Han Y; Li X; Zhang H; Yao Z; Zhou J; Mu R; Zhao J Semin Arthritis Rheum; 2024 Aug; 67():152483. PubMed ID: 38843569 [TBL] [Abstract][Full Text] [Related]
14. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis]. Han YY; Jiang T; Zhang ZH; Li W; Jiang YD; Lu CC; Fei Y; Chen B Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):422-425. PubMed ID: 36949709 [TBL] [Abstract][Full Text] [Related]
15. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005 [TBL] [Abstract][Full Text] [Related]
16. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008 [TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report. Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214 [TBL] [Abstract][Full Text] [Related]
19. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240 [TBL] [Abstract][Full Text] [Related]
20. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review]. Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559 [No Abstract] [Full Text] [Related] [Next] [New Search]